Oral TRT Prolactin Monitoring Under the Tlando Label

Oral TRT Prolactin Monitoring Under the Tlando Label

Estimated reading time: 8 minutes

Key takeaways

• The FDA-approved Tlando label instructs clinicians to check serum prolactin before initiation and again 3–4 months after starting; discontinue if prolactin remains elevated after starting.
• Short-term data show occasional, modest prolactin rises (about 6.3% of participants; mean ~+7.0 ng/mL in a 24-day study), prompting label-level monitoring guidance.
• Injectable TRT products generally do not include a similar prolactin monitoring requirement in their labels.
• Monitoring still centers on testosterone levels, hematocrit, blood pressure, and prostate parameters; prolactin is a formulation-specific add-on for Tlando.
• Plan baseline and 3–4 month labs with your clinician to align therapy and follow-up with label guidance.

TRT Monitoring Protocols for Prolactin in Oral Formulations: What Tlando’s FDA Label Means for Patients

Oral testosterone undecanoate has changed how some men approach testosterone replacement therapy (TRT). But Tlando (oral testosterone undecanoate), approved by the FDA in 2022, arrives with a unique monitoring note that often surprises patients and clinicians alike: check serum prolactin before starting and again 3–4 months after initiation, with discontinuation advised if prolactin remains elevated. That language appears in the FDA-approved prescribing information and is not emphasized in most injectable TRT protocols. This article unpacks what that means in practice, how we got here, and what open questions remain for oral TRT users.

Why Prolactin Is Entering the TRT Conversation Now

Prolactin is a pituitary hormone. Outside of specific clinical contexts, it is not routinely emphasized in standard TRT monitoring. That changed for oral testosterone undecanoate with Tlando, whose FDA label explicitly instructs clinicians to check serum prolactin levels before starting therapy and again after 3–4 months of treatment, and to discontinue if levels remain elevated after initiation.

This labeling followed clinical trial findings that suggested an inconsistent but real signal for prolactin increases during short-term exposure. The FDA addressed the signal in the Warnings and Precautions section of Tlando’s label and retained that language in a subsequent 2025 label update. This is a formulation-specific requirement, not a universal standard across all TRT modalities. For men exploring oral TRT, that means prolactin is a practical monitoring step that may influence whether you remain on a given regimen.

What the FDA Required After Tlando’s Approval

When Tlando (NDA 208088) was approved in 2022, the FDA mandated several postmarketing studies under Section 505(o)(3) of the FDCA. Among those were studies related to potential hypothalamic–pituitary–adrenal (HPA) axis effects, reflecting the agency’s interest in endocrine consequences beyond serum testosterone.

At the same time, the FDA’s review flagged increased prolactin as a safety signal. Rather than requiring a separate postmarketing study solely devoted to prolactin, the agency incorporated a clear action into the label: screen prolactin before initiation, reassess 3–4 months into therapy, and discontinue if it remains elevated after starting. A 2025 label update retained this approach, providing a defined pathway for surveillance and action while longer-term data mature.

What the Clinical Data Show So Far

• In a 24-day clinical study of Tlando, 6.3% (6 of 95) of participants experienced increases in serum prolactin, with a mean change of approximately +7.0 ng/mL from baseline.
• A longer 4-month study did not reassess prolactin after screening, so longitudinal changes beyond the initial period are not well characterized in the pivotal data.
• The FDA considered the prolactin findings inconsistent but noteworthy enough to address through labeling.

Two caveats matter for interpretation:

• The label does not define a numeric threshold for “elevated” prolactin. Reference intervals vary across labs, so the decision to stop therapy hinges on clinician judgment and patient-specific context.
• The label cautions against use in patients with prolactin-dependent tumors, underscoring the potential clinical weight of prolactin changes in certain conditions.

Bottom line: the data suggest occasional, modest increases in prolactin with Tlando in the short term, with an FDA-mandated monitoring protocol. The clinical significance of small, asymptomatic increases remains uncertain, and longer-term data are still developing.

How Monitoring Differs for Oral TRT vs. Injectables

Most TRT programs, whether topical or injectable, focus on:

• Achieving physiologic testosterone levels and rechecking after initiation or dose changes
• Watching hematocrit/hemoglobin to reduce the risk of erythrocytosis
• Checking blood pressure and cardiovascular risk factors
• Assessing prostate health parameters as clinically indicated

For Tlando specifically, the label highlights:

• Serum testosterone: measure about 3–4 weeks after starting to ensure levels fall within the target range (the Tlando label uses a window of approximately 300–1080 ng/dL).
• Serum prolactin: check prior to initiation and again 3–4 months into therapy; discontinuation is advised if prolactin remains elevated after starting.

Injectable testosterone products generally do not include an FDA-labeled requirement to monitor prolactin in the same way. That difference does not make injectables universally simpler or risk-free—it just means prolactin is not a labeled focus. Regardless of modality, ongoing assessment of hematocrit and cardiovascular risk is core to responsible TRT care.

Practical Implications for Patients Considering Oral TRT

• Baseline labs with intention: If prolactin will inform whether you start or continue Tlando, plan the test before initiation. Ask how “elevated” will be defined within your lab’s reference interval and clinical context.
• The 3–4 month checkpoint: Put a date on the calendar for both testosterone and prolactin checks. Clarify in advance what will happen if prolactin is elevated—repeat testing, additional evaluation, a pause, or a switch in modality.
• Interpretation matters: Small increases may be clinically irrelevant; persistent or marked elevations may prompt action. With no absolute cut-off in the label, real-world decisions rely on clinician judgment and your overall health picture.
• The monitoring trade-off: Some patients prefer oral formulations to avoid injections; others prioritize fewer lab-specific requirements. Understanding how prolactin fits into follow-up can clarify your choice.
• Dosing context: Tlando is administered 225 mg twice daily with food. This can influence adherence and lab timing; discuss how and when to draw labs relative to dosing and meals.

Open Questions: HPA Axis and Long-Term Safety

The FDA’s postmarketing requirements for Tlando include studies examining potential HPA axis effects. While prolactin is related to the pituitary, the HPA axis covers a broader endocrine system. These commitments reflect interest in endocrine ripple effects of oral testosterone undecanoate beyond testosterone itself.

Key uncertainties to watch:

• Do oral formulations uniquely affect prolactin compared with injectables?
• What is the long-term trajectory of prolactin changes beyond a few months of therapy?
• Which patients, if any, are more prone to sustained prolactin elevations on oral TU?
• Do elevations remain subclinical or translate into meaningful symptoms or risks in specific subgroups?

As evidence from real-world use and postmarketing work grows, labels could evolve. For now, the prolactin language remains in place and provides concrete guidance for early monitoring.

How Taurus Meds Thinks About “Testosterone Prolactin Levels” in Care Plans

In practice, the label’s direction translates into a simple, time-bound check for oral TU users: screen prolactin at baseline, and reassess after 3–4 months. That’s a manageable addition to the standard testosterone, hematocrit, blood pressure, and prostate monitoring you and your clinician might already be doing.

For men deciding between oral and injectable TRT, the difference is more about coordination than complexity. If you value oral dosing, plan for the extra prolactin data point. If minimizing lab variability is your priority, injectables may feel more familiar. Either path benefits from a structured lab schedule and clear follow-up conversations.

Taurus Meds supports patients in building these schedules, aligning tests with label guidance, and coordinating with clinicians so that therapy decisions are made with the right information at the right time.

Conclusion

Oral testosterone undecanoate via Tlando introduced a specific, FDA-labeled expectation: monitor serum prolactin before starting, then again 3–4 months into therapy, and discontinue if levels remain elevated after initiation. The evidence behind that instruction is limited and somewhat inconsistent, but the label treats the signal seriously enough to structure care around it.

Injectable TRT modalities do not share this prolactin requirement, which may factor into treatment selection for some men. Regardless of the route, a careful monitoring plan remains essential: track testosterone levels, hematocrit, cardiovascular parameters, and clinician-directed prostate assessments. The right regimen is the one that aligns with your health status, preferences, and ability to engage with monitoring.

As postmarketing studies mature—particularly those related to the HPA axis—expect the evidence base to grow. For now, the safest path is to follow the label, recognize uncertainty where it exists, and make shared decisions with your care team.

Disclaimer

This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication or monitoring plan without consulting a qualified healthcare professional.

Sources

• FDA prescribing information for Tlando (2022 label)
• FDA Summary Review for Tlando (NDA 208088)
• FDA prescribing information for Tlando (2025 s002 label update)
• Tlando HCP: Efficacy